How PEDF prevents angiogenesis: a hypothesized pathway
Introduction
Angiogenesis, the process in which new capillaries form by sprouting from pre-existing ones, occurs normally during embryogenesis and pathologically in tumor growth, diabetic retinopathy, wound healing, psoriasis and rheumatoid arthritis [1], [2], [3], [4], [5], [6], [7], [8]. Generally, angiogenesis is exquisitely controlled in most healthy tissues through a finely tuned balance between pro- and anti-angiogenic factors.
Pathogenic angiogenesis plays an important role in disease progression. It is well known that tumors cannot grow beyond 2–3 mm in diameter without forming new blood vessels. Not restricted to tumors, the neovascularization occurring in diabetic retinopathy threatens the visions of more than 7 million people in the USA alone [1]. Actually, tumor and diabetes are the two most threatening diseases for human health. The ability to control neovascularization would offer a unique opportunity to impact a wide variety of physiological and pathological functions. Thus, preventing neovascularization becomes a fascinating goal for both tumor and diabetic therapy [8], [9], [10], [11], [12], [13], [14]. Developing antiangiogenic factors is becoming a more and more attractive approach for the therapy of tumor, diabetic retinopathies, and other neovascularization-related diseases.
Pigment epithelium-derived factor (PEDF), a 418-amino acid 50 KDa glycoprotein first identified in 1987 by Tombran-Tink and Johnson in conditioned medium from fetal human retinal pigment epithelium (RPE) cell culture, is among the most potent natural antiangiogenic factors, as it specifically inhibits both the migration and proliferation of endothelial cells [15]. The antiangiogenic activity of PEDF is selective because it is effective against newly forming vessels but spares existing ones, and it is reversible. In specific, as an effective anti-angiogenic factor for clinic purposes, PEDF has the following advantages:first, it is not expected to activate drug-resistance genes, and thus offers the potential for effective long-term anti-angiogenic therapy. Second, due to its tolerance in the body, it is unlikely to produce the toxic side effects of synthetic inhibitors. Finally, given its neurotrophic activity, PEDF has the additional advantage of preserving neurons from the damage often caused by vascular disease of the nervous system. In light of PEDFs great promise for anti-angiogenesis, understanding its fundamental mechanism holds the promise of effective therapeutic approaches for treating neovascularization-related diseases.
Some researchers have proposed that maintaining a balance between the pro and anti-angiogenic factors is critical for the regulation of angiogenesis [16]. The expression and the role of angiogenic factors in retinal neovascularization have been well established. Normal angiogenesis requires the coordination of growth factor receptors and integrins, leading to the activation of down stream signals in endothelial cells [17]. Although integrins and growth factor receptors can independently propagate intracellular signals [18], [19], [20], it appears that a synergy between signals initiated by the extracellular matrix (ECM) and growth factors enhances their separately induced angiogenesis [20]. In addition, protein phosphatases such as protein tyrosine phosphatase (PTP) and protein kinases like FAK, Akt, Src, and MAPK play key roles in the cross-talk between the growth factor and integrin pathways [20]. Thus, there are two possible means to inhibit angiogenesis: one is to target the receptors of growth factors; the other is to disrupt the activation of integrin. PEDF is the most potential natural antiangiogenic factor found up to now [15]. However, how it is that PEDF inhibits new blood vessels formation has remained uncertain. Some evidence has indicated that PEDF can inhibit the migration, proliferation, and even permeability induced by VEGF, in vitro or in vivo, and thereby inhibit angiogenesis by interacting with specific cell surface receptors [21], [22], however, no such receptor has been reported to date.
Section snippets
PEDF exerts its function via integrins
Here we hypothesize that integrin can serve as the receptor of PEDF. Collagen is an ideal angiogenic scaffold since angiogenesis depends on proper collagen biosynthesis and cross-linking. Collagen can itself trigger angiogenesis by binding with some integrins, which then serve as collagen receptors [23]. In vivo, PEDF interacts with the ECM proteins such as collagen [24] and heparin [25]. Therefore, it is reasonable to hypothesize that PEDF can regulate the angiogenesis induced by VEGF or other
Suggestions for experimentation
In this hypothesis we put forward a possible mechanism by which PEDF exerts its function in vivo via interaction with integrins. To test this hypothesis, the following experiments will be helpful. First, do an in vitro PEDF–integrin binding experiment to observe whether PEDF can directly bind to integrins or not. Second, determine in an endothelial cell system analysis whether PEDF still can bind to the cell surface after integrins are blocked with integrin antibody. Third, analyse whether PEDF
References (35)
- et al.
Therapeutic prospects for PEDF: more than a promising angiogenesis inhibitor
Trends Mol. Med.
(2003) PEDF: anti-angiogenic guardian of ocular function
Trends Mol. Med.
(2002)- et al.
Recent advances in angiogenesis, anti-angiogenesis and vascular targeting
Trends Pharmacol. Sci.
(2002) - et al.
Angiogenesis as a target for cancer therapy
Hematol. Oncol. Clin. North Am.
(2002) Aberrant tumor vasculature and angiogenesis: new opportunities for cancer therapy
Drug Discov. Today
(2003)- et al.
Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization
FEBS Lett.
(2001) - et al.
Binding of pigment epithelium-derived factor (PEDF) to retinoblastoma cells and cerebellar granule neurons. Evidence for a PEDF receptor
J. Biol. Chem.
(1999) - et al.
Angiogenesis in collagen I requires alpha2betal ligation of a GFP∗GER sequence and possibly p38 MAPK activation and focal adhesion disassembly
J. Biol. Chem.
(2003) - et al.
Mapping the type I collagen-binding site on pigment epithelium-derived factor. Implications for its antiangiogenic activity
J. Biol. Chem.
(2002) - et al.
Recognition of the N-terminal modules of thrombospondin-1 and thrombospondin-2 by alpha 6beta 1 integrin
J. Biol. Chem.
(2003)
Thrombospondin-bound integrin-associated protein (CD47) physically and functionally modifies integrin alphaIIbbeta3 by its extracellular domain
J. Biol. Chem.
TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism
Cell
PEDF: a multifaceted neurotrophic factor
Nat. Rev. Neurosci.
PEDF: raising both hopes and questions in controlling angiogenesis
Proc. Natl. Acad. Sci. USA
Angiogenesis in health and disease
Nat. Med.
Angiogenesis in health and disease: insights into basic mechanisms and therapeutic opportunities
J. Dent. Educ.
Tumor angiogenesis
Bull. Cancer
Cited by (51)
Endosome-triggered ion-releasing nanoparticles as therapeutics to enhance the angiogenic efficacy of human mesenchymal stem cells
2020, Journal of Controlled ReleaseCitation Excerpt :hMSCs and HDFs play critical roles in the inflammatory and re-epithelialization phases of wound-healing [54,55] and showed significantly enhanced proliferation and cell viability after supplementation with ETIN CM (Fig. 4H–O). Based on Figs. 3 and 5 and S8, we concluded that enhanced VEGF, FGF2, pentraxin 3 [28], endoglin [29], endothelin-1 [30], FGF acidic [31], FGF basic [31], and uPA [32] secreted from ETIN-hMSCs could have improved the wound-healing process compared with conventional treatment; additionally, the anti-angiogenic protein, serpin F1 was downregulated [33]. Similar to the in vitro test, as shown in Fig. 4A–G, the enhanced hMSC survival rate in the ETIN-hMSC group could have increased the therapeutic effect of ETIN (Figs. 5 and 6).
An injectable elastin-based gene delivery platform for dose-dependent modulation of angiogenesis and inflammation for critical limb ischemia
2015, BiomaterialsCitation Excerpt :Furthermore, eNOS treatment groups also showed an increasing level of serpinF1, an anti-angiogenic factor. SerpinF1 is known to inhibit the migration and proliferation of endothelial cells induced by VEGF [33], and then further inhibits angiogenesis by interacting with specific cell surface receptors. This anti-angiogenic activity of serpinF1 is critical for the regulation of angiogenesis.
Expression of pigment epithelium-derived factor and tumor necrosis factor-α is correlated in bladder tumor and is related to tumor angiogenesis
2013, Urologic Oncology: Seminars and Original InvestigationsCitation Excerpt :The result is concordant with that in researches involving glioma [19], neuroblastoma [20], and prostate cancer [7]. Nonetheless, it is still unclear how distinctive factors interact in the antiangiogenic pathway PEDF mediates [18], and we have thus involved another potent proangiogenic factor, TNF-α, aiming for identifying whether the element functions in middle of the complicated pathway. TNF-α is a key cytokine modulating immunity, cellular organization, and inflammation.
Gene therapy of endometriosis introduced by polymeric micelles with glycolipid-like structure
2012, BiomaterialsCitation Excerpt :However, how PEDF inhibits new blood vessels formation was still uncertain. Ren et al. [51] hypothesized that integrin may serve as the receptor of PEDF to inhibit angiogenesis by blocking phosphorylation through inactivating the protein kinase, while other researcher thought PEDF could exert its anti-angiogenic activity in bovine retinal endothelial cells (BRECs) through inhibiting of PI3K/Akt signaling pathway [52]. In our study, we did not explore the mechanism of PEDF in endometriosis, further experiments is being done.